Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Medivation/Astellas’ Xtandi A Tough Rival For J&J’s Zytiga

Related Content

Data At ASCO From J&J Zytiga Trial’s Early End = Intel For Medivation’s MDV3100 Program

Jun 18 2012

Xtandi Gets Speedy Approval; Medivation/Astellas Already Prepped For Launch

Aug 31 2012

Phase III Data AFFIRM Safety As Well As Survival For MDV3100

Jan 31 2012

Medivation Aims To Capture Prostate Cancer Market, One Trial At A Time

Nov 14 2011

Related Companies

Medivation, Inc.

Astellas Pharma, Inc.

Johnson & Johnson

Sanofi

Dendreon Corporation

AstraZeneca PLC

Abbott

Merck & Co., Inc.

Additional Topics

Research & Development BioPharmaceutical

More from R&D

More from Pink Sheet

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window